Session » Reproductive Issues in Rheumatic Disorders Poster

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM: Abstract Number: 0959

Assessing the Association Between Hydroxychloroquine and Preeclampsia Risk in SLE Pregnancies Using Administrative Claims Data

9:00AM-10:30AM: Abstract Number: 0966

Assessment and Application of Royal College of Obstetricians and Gynaecologists (RCOG) Risk Scores in the Prevention of Venous Thromboembolism Peri- and Postpartum in Systemic Lupus Erythematosus

9:00AM-10:30AM: Abstract Number: 0958

Azathioprine Metabolite Levels and Outcomes During Pregnancies in Women with Rheumatic Disease

9:00AM-10:30AM: Abstract Number: 0945

Contraception Documentation Patterns for Adult Females with Juvenile Idiopathic Arthritis on Teratogenic Medications in the Rheumatology Informatics System for Effectiveness (RISE) Registry

9:00AM-10:30AM: Abstract Number: 0956

Contribution of Antibody Titers/Specificities to Adverse Pregnancy Outcomes in a Multicenter Prospective Study of anti-Ro Positive Mothers

9:00AM-10:30AM: Abstract Number: 0947

Development of a Person-Centered Family Planning Decision Aid for Women with Rheumatic Diseases

9:00AM-10:30AM: Abstract Number: 0940

Effect of an 8-week Tailored Physical Therapy Program on Sexual Function in Women with Systemic Sclerosis and Idiopathic Inflammatory Myopathies: A Pilot Controlled Study

9:00AM-10:30AM: Abstract Number: 0942

Evaluation of Ovarian Reserve Using Anti-Mullerian Hormone Levels in Adolescents with Systemic Rheumatic Disease Compared to Healthy Controls

9:00AM-10:30AM: Abstract Number: 0963

Exploring Reasons for Non-Use of Hydroxychloroquine in SLE Pregnancy

9:00AM-10:30AM: Abstract Number: 0948

Fertility and the Use of Assisted Reproductive Technologies: Perceptions, Thoughts and Experiences of Men and Women with Rheumatic Disease

9:00AM-10:30AM: Abstract Number: 0964

High Rates of Fetal Growth Restriction in Systemic Lupus Erythematosus Pregnancies

9:00AM-10:30AM: Abstract Number: 0944

Inconsistent Family Planning Documentation in Women with Interstitial Pneumonia with Autoimmune Features (IPAF)

9:00AM-10:30AM: Abstract Number: 0943

Increased Prevalence of Thrombotic Events in Anti-Phospholipid Antibody-Positive SLE Patients on Estrogen-Containing Contraception

9:00AM-10:30AM: Abstract Number: 0953

Increased Risk of Preterm Delivery Phenotypes and Hypertensive Disorders of Pregnancy in First Deliveries of Patients with Systemic Vasculitis

9:00AM-10:30AM: Abstract Number: 0968

Neuropsychological Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-administered Multidisciplinary Questionnaire in a Monocentric Cohort

9:00AM-10:30AM: Abstract Number: 0950

Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry

9:00AM-10:30AM: Abstract Number: 0967

Patterns of Breastfeeding Among Women with and Without Systemic Lupus Erythematosus

9:00AM-10:30AM: Abstract Number: 0939

Pilot Study: A Novel Method for Cervical Health Monitoring in African American Women with Systemic Lupus Erythematosus (SLE) Using a Self- Sampling Brush to Assess Cervical HPV Infection and Cervical Cytology

9:00AM-10:30AM: Abstract Number: 0952

Pregnancy Course and Outcomes of Patients with Polymyositis and Dermatomyositis (PM/DM) in Our Institution

9:00AM-10:30AM: Abstract Number: 0965

Pregnancy Outcomes in a Diverse Lupus Cohort

9:00AM-10:30AM: Abstract Number: 0960

Serum C3 Level and Glucocorticoid Dose Are Risk Factors for Preterm Birth in Patients with Systemic Lupus Erythematosus

9:00AM-10:30AM: Abstract Number: 0941

Surveying Adolescents with Rheumatic Disease for At-Risk Behavior

9:00AM-10:30AM: Abstract Number: 0949

Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic CHallenge (SWITCH): The Systemic Lupus International Collaborating Clinics Experience

9:00AM-10:30AM: Abstract Number: 0946

The Impact of Pregnancy Planning and Medical Readiness on Reproductive Outcomes in Women with SLE

9:00AM-10:30AM: Abstract Number: 0961

The Use of Belimumab Before and During Pregnancy in Patients with Systemic Lupus Erythematosus: An Italian Multicenter Case-series

9:00AM-10:30AM: Abstract Number: 0957

Timeliness of Fetal Echocardiography for Congenital Heart Block Detection in Anti-Ro/La-Positive Pregnancies

9:00AM-10:30AM: Abstract Number: 0955

Unfavorable Pregnancy Outcome Is Significantly Associated with Corticosteroid Exposure During Pregnancy in Women with RA: Analysis of the Prospective GR2 Cohort

9:00AM-10:30AM: Abstract Number: 0969

Use of Gonadotropin-releasing Hormone Agonists for Ovarian Preservation in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus: A Meta-analysis

9:00AM-10:30AM: Abstract Number: 0962

Variability in Racial Disparities in Pregnancy Outcomes in Women with SLE by Diagnosis Algorithm

9:00AM-10:30AM: Abstract Number: 0954

What Drives the BASDAI in Pregnant Patients with Axial Spondyloarthritis? A Pooled Analysis of Four European Pregnancy Registries

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].